Clinical trials: RSV
Respiratory Syncytial Virus Prevention
A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants
The purpose of the study is to evaluate the efficacy of study vaccine in the prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-confirmed RSV mediated- lower Respiratory Tract Disease (LRTD) over one RSV…
- Trial name
- NCT05242432
- Testing
- Ad26/protein preF RSV Vaccine
- Where
- 30 sites in Japan
- Volunteers
- 2,192 people
- Sponsor
- Janssen Pharmaceutical K.K.
Respiratory Syncytial Virus (RSV)
RSV-F Vaccine Dose Ranging Study in Young Women
The purpose of this study is to evaluate the immunogenicty and safety of an RSV-F protein nanoparticle vaccine, with out without aluminum, in healthy women of child-bearing potential.
- Trial name
- NCT01704365
- Testing
- Low dose RSV-F Vaccine with Adjuvant, Low dose RSV-F Vaccine without Adjuvant, High dose RSV-F Vaccine with Adjuvant
- Where
- 4 sites in United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Novavax
Respiratory Syncytial Virus (RSV)
Systems Biological Analysis of Immune Responses to RSV Vaccine
The purpose of this study is to characterize the immune response to the FDA-approved mRNA-based RSV vaccine in adults ≥60 years of age, using a systems biology approach.
- Trial name
- RSV SB (NCT07185399)
- Testing
- Moderna RSV vaccine
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Emory University
RSV Infection
A Study of EDP-938 in Healthy Subjects
This randomized, double-blind, placebo-controlled study will assess the safety, tolerability, and pharmacokinetics of single and multiple orally administered doses of EDP-938 in healthy adult subjects
- Trial name
- NCT03384823
- Testing
- EDP-938
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Respiratory Infections, Acute, Respiratory Syncytial Virus
RSV Disease in the Elderly
Respiratory syncytial virus (RSV) causes sickness and deaths in older people every winter. This study will investigate how aging affects the body's immune response (body's response to disease) to RSV.
- Trial name
- NCT00246480
- Where
- United States
- Volunteers
- 1,401 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Virus Diseases, Pneumonia
Universal Anti-Viral Vaccine for Healthy Elderly Adults
This protocol tests the safety and efficacy of a novel universal vaccine concept called "allo-priming" which is designed to protect elderly adults from progression of any type of viral infection, including possible protection…
- Conditions
- Virus Diseases, Pneumonia, COVID-19 Respiratory Infection, RSV Pneumonia
- Trial name
- ALLOPRIME (NCT04441047)
- Testing
- AlloStim
- Where
- 4 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mirror Biologics, Inc.
Respiratory Syncytial Virus Infections
Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children
Human respiratory syncytial virus (RSV) is a common cause of upper respiratory tract illnesses as well as more severe lower respiratory illnesses, including bronchiolitis and pneumonia.
- Trial name
- NCT01459198
- Testing
- RSV MEDI ΔM2-2 vaccine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
RSV
Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in Adults
The purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of bivalent RSV prefusion F vaccine (RSV vaccine) in adults. Participants will be randomized 1:1 to either RSV vaccine or no RSV vaccine.
- Trial name
- DAN-RSV (NCT06684743)
- Testing
- RSV prefusion F protein-based vaccine
- Where
- 3 sites in Denmark, Spain
- Volunteers
- 690,000 people, healthy volunteers welcome
- Sponsor
- Tor Biering-Sørensen